Pfizer signs $75M Trovan settlement; Lucentis boosts vision in new disease;

> Pfizer signed a settlement worth up to $75 million with Nigeria's Kano state on Thursday related to a 1996 meningitis drug trial, the two parties said in a joint statement. Report

> Roche's eye disease drug Lucentis helped improve vision in patients suffering from a condition known as central retinal vein occlusion, Roche's Genentech unit said. Report

> Human Genome Sciences said it intends to raise $310 million from its stock offering, which it's pricing at $14 a share, a 4 percent discount from today's closing price. Report

> India's Aurobindo Pharma Friday reported a surge in fiscal first-quarter consolidated net profit to 1.67 billion rupees ($34.6 million) from 164.2 million rupees a year earlier. Report

> United Therapeutics got the FDA nod for its fourth product, Tyvaso, to treat pulmonary arterial hypertension, rounding out its drug franchise for the potentially fatal disease. Report

> Glenmark Pharmaceuticals secured FDA approval for its version of GlaxoSmithKline's ointment Aclovate. Report

Biotech News

> With its stock price up and its RNA technology showing promise for Duchenne Muscular Dystrophy and bioterror programs, a bullish AVI Biopharma announced that it will move its headquarters staff and some research work from Portland to Bothell, WA, where it plans to tap into Seattle's biotech labor force. Report

> Rockville, MD-based Supernus has raised $35 million from an unnamed drug development partner. Supernus sold the future royalties from a new product it will help the partner develop. And that brings its haul of non-dilutive cash to $110 million for the last 17 months, according to a report in the Washington Business Journal. Report

> GlaxoSmithKline and Genmab's rheumatoid arthritis drug Arzerra (ofatumumab) performed well in a Phase III trial in patients who had not responded to the common RA drug methotrexate. Report

> Shares of Lundbeck slid after the Danish pharmaceutical group and Solvay announced that they were sounding the death knell on a late-stage drug program for schizophrenia. Report

> Several weeks ago Discovery Laboratories came to terms with the fact that its lead drug, Surfaxin, was unlikely to gain FDA approval anytime soon. The company chose to focus two pipeline programs--Surfaxin LS and Aerosurf. Now it looks like Discovery will need more funding to support those two programs. Report

And Finally... Women, particularly African-American women, see greater cardiovascular health benefits from exercise than men do. Report

Suggested Articles

Saturday, AstraZeneca revealed more of the data that convinced the FDA to green-light Calquence in previously untreated chronic lymphocytic leukemia.

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.